Teduglutide(CAS#197922-42-2)

 Teduglutide(CAS#197922-42-2)

Pharmacological effects: It can reduce gastric emptying and secretion, and regulate the growth, proliferation and repair of small intestinal lining cells, increase the number of small intestinal lining cells, thereby increasing small intestinal absorption and reducing diarrhea.
Clinical application: for the treatment of short bowel syndrome in adults, it is the first drug recommended for this rare but extremely debilitating disease.
Pharmacokinetics: The metabolism of teduglutide is not fully understood. Since it is a peptide, it may follow the main mechanism of peptide metabolism. There are currently no specific organs identified as the primary route of elimination.
Adverse reactions: the most commonly reported adverse reactions were abdominal pain and bloating (45%), respiratory tract infection (28%), nausea (26%), injection site reactions (26%), headache (16%), and vomiting (14%).
Precautions: Contraindicated in patients with hypersensitivity to the active substance or any of the listed excipients or trace residues of tetracycline, and in patients with active or suspected malignancy. Patients with colorectal polyps, gastrointestinal tumors, pancreatic diseases, intestinal obstruction, fluid overload, etc., need special attention when using them, and should be evaluated on a case-by-case basis. Pregnant and lactating women are best avoided, and safety and efficacy in children under 1 year of age have not been established.